XML 30 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation and Summary of Significant Accounting Policies (Details 2) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Rollforward of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3)        
Balance at beginning of period     $ 17,527,000  
Total gains (losses) (realized or unrealized):        
Included in earnings     (1,471,000)  
Included in other comprehensive income (loss)     2,373,000  
Purchases, issuances, sales, and settlements:        
Sales     (18,329,000)  
Settlements     (100,000)  
Assets held for sale        
Accelerated depreciation of assets held for sale 1,100,000   1,400,000  
Impairment loss     800,000  
Non-cash charges     2,200,000  
Product sales allowances and accruals        
Discounts and chargebacks 6,644,000 3,601,000 19,382,000 9,400,000
Government and other rebates 1,595,000 2,120,000 4,487,000 6,897,000
Medicaid rebate reserve adjustment (861,000) (3,026,000) (621,000) (2,532,000)
Returns (1,122,000) 354,000 (1,680,000) 1,022,000
Total provision for product sales allowances and accruals 6,256,000 3,049,000 21,568,000 14,787,000
Total gross product sales 22,432,000 18,851,000 65,872,000 54,692,000
Total provision for product sales allowances and accruals as a percent of total gross product sales 28.00% 16.00% 33.00% 27.00%
Typical average period from time of product sale to payment of rebate, up to or longer than     6 months  
Current expiration period for packaged products     4 years  
Reduction of reserve for product returns 1,300,000   2,100,000  
Expiration period for certain manufactured lots     2 years  
Reduction in Medicaid rebate reserves 900,000 3,000,000 600,000 2,500,000
Reduction in estimated medicaid rebate reserve, impact per basic and diluted share (in dollars per share) $ 0.04 $ 0.14 $ 0.03 $ 0.14
Product returns reserve applied to gross sales (1,100,000) 400,000 (1,700,000) 1,000,000
Reduction in estimated product returns reserve, impact per basic and diluted share (in dollars per share) $ 0.06   $ 0.10  
Cost of product sales
       
Assets held for sale        
Non-cash charges     2,000,000  
Research and development
       
Assets held for sale        
Non-cash charges     $ 200,000